Skip to main content

Sirolimus Protein-Bound Particles

Placeholder slot
 (sih-ROH-lih-mus PROH-teen-bownd PAR-tih-kulz)

This page contains brief information about sirolimus protein-bound particles and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
Fyarro
FDA Approved
Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Sirolimus protein-bound particles are approved to treat adults with:

Sirolimus protein-bound particles are a form of sirolimus contained in nanoparticles (very tiny particles of protein). The drug is also called nanoparticle albumin-bound rapamycin. This form may work better than other forms of sirolimus and have fewer side effects.

Sirolimus protein-bound particles are also being studied in the treatment of other types of cancer.

More About Sirolimus Protein-Bound Particles

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Clinical Trials Accepting Patients

Find Clinical Trials for Sirolimus Protein-bound Particles - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated: